ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1

Approximately 80% of human breast carcinomas present as oestrogen receptor α-positive (ER+ve) disease, and ER status is a critical factor in treatment decision-making. Recently, single nucleotide polymorphisms (SNPs) in the region immediately upstream of the ER gene (ESR1) on 6q25.1 have been associated with breast cancer risk. Our investigation of factors associated with the level of expression of ESR1 in ER+ve tumours has revealed unexpected associations between genes in this region and ESR1 expression that are important to consider in studies of the genetic causes of breast cancer risk. RNA from tumour biopsies taken from 104 postmenopausal women before and after 2 weeks treatment with an aromatase (oestrogen synthase) inhibitor was analyzed on Illumina 48K microarrays. Multiple-testing corrected Spearman correlation revealed that three previously uncharacterized open reading frames (ORFs) located immediately upstream of ESR1, C6ORF96, C6ORF97, and C6ORF211 were highly correlated with ESR1 (Rs = 0.67, 0.64, and 0.55 respectively, FDR<1×10−7). Publicly available datasets confirmed this relationship in other groups of ER+ve tumours. DNA copy number changes did not account for the correlations. The correlations were maintained in cultured cells. An ERα antagonist did not affect the ORFs' expression or their correlation with ESR1, suggesting their transcriptional co-activation is not directly mediated by ERα. siRNA inhibition of C6ORF211 suppressed proliferation in MCF7 cells, and C6ORF211 positively correlated with a proliferation metagene in tumours. In contrast, C6ORF97 expression correlated negatively with the metagene and predicted for improved disease-free survival in a tamoxifen-treated published dataset, independently of ESR1. Our observations suggest that some of the biological effects previously attributed to ER could be mediated and/or modified by these co-expressed genes. The co-expression and function of these genes may be important influences on the recently identified relationship between SNPs in this region and breast cancer risk.

[1]  M. Martin,et al.  Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. , 2004, The Journal of endocrinology.

[2]  R. Blamey,et al.  Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. , 1996, European journal of cancer.

[3]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[4]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[6]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[8]  M. Dowsett,et al.  ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. , 2008, Endocrine-related cancer.

[9]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. N. Available.  World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.

[11]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[12]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[13]  E. Levin,et al.  Extranuclear steroid receptors: nature and actions. , 2007, Endocrine reviews.

[14]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[15]  Michael Jones,et al.  Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. , 2011, Journal of the National Cancer Institute.

[16]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[18]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[19]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[20]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[21]  E. Liu,et al.  An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.

[22]  M. Gottardis,et al.  Regulation of estrogen receptor expression , 2004, Breast Cancer Research and Treatment.

[23]  Hongbing Shen,et al.  Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry. , 2011, Cancer research.

[24]  O. Lingjaerde,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[25]  A. Ashworth,et al.  A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines , 2009, Breast Cancer Research and Treatment.

[26]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[27]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[28]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[29]  I. Amit,et al.  Comprehensive mapping of long range interactions reveals folding principles of the human genome , 2011 .

[30]  R. Simon,et al.  Controlling the number of false discoveries: application to high-dimensional genomic data , 2004 .

[31]  Anne Vincent-Salomon,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[32]  Clement Adebamowo,et al.  Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus , 2010, PLoS genetics.

[33]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[34]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[35]  Marc E. Lippman,et al.  GREB1 is a critical regulator of hormone dependent breast cancer growth , 2005, Breast Cancer Research and Treatment.

[36]  Wei Zheng,et al.  Alteration at translational but not transcriptional level of transferrin receptor expression following manganese exposure at the blood-CSF barrier in vitro. , 2005, Toxicology and applied pharmacology.

[37]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[38]  A. Ashworth,et al.  Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.

[39]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[40]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Hampton,et al.  Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.

[42]  A. Wakeling,et al.  ICI 182,780, a new antioestrogen with clinical potential , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  T. Ichida.  World Medical Association declaration of Helsinki , 1991, Gastroenterologia Japonica.

[44]  Debashis Ghosh,et al.  A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. , 2008, Neoplasia.

[45]  S. Angeloni,et al.  Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. , 2004, The Journal of endocrinology.

[46]  M. Dowsett,et al.  A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[48]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[49]  A. Ashworth,et al.  An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.

[50]  Alberto Costa,et al.  Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer , 2010, Breast Cancer Research and Treatment.

[51]  A. Ashworth,et al.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.

[52]  Deborah Hughes,et al.  Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.

[53]  M. Dowsett,et al.  Selection of REFERENCE Genes for Normalization of qRT-PCR Data Derived From FFPE Breast Tumors , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[54]  M. Dowsett,et al.  Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer , 2011, Clinical Cancer Research.

[55]  M. Moran,et al.  Large-scale mapping of human protein–protein interactions by mass spectrometry , 2007, Molecular systems biology.

[56]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[57]  P. Darbre,et al.  Effect of estradiol on human breast cancer cells in culture. , 1983, Cancer research.

[58]  G. Lazennec,et al.  Characterization of the transcription start point of the trout estrogen receptor-encoding gene: evidence for alternative splicing in the 5' untranslated region. , 1995, Gene.